Potential opportunities for treatment of metabolic syndrome withalpha-lipoic acid (Berlithion®300)
https://doi.org/10.14341/2071-8713-5240
Abstract
There are a lot of experi mental data confirmed the influence of alpha-lipoi с acid on activity of AMPK enzyme, receptors PPARα/γ and uncoupling proteins that prev ent oxidative phosphorylation (UCPl). AMPK is the enzyme responsible for food intake and energy expenditure in hypothalamus as w ell as in peripheral adipose tissue. PPARγ is the key modulator of lipid ho meostasis and adipocyte differentiation. UCPl is located in the brown adipose tissue and provides termogenesis. Via regulation of mentioned biological targets alpha-lipoic acid (Berlithion®300) lowers insulinresistance, favors weight losing process and improvement of blood lipid profile.
References
1. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet, 2005, 365:1415-28.
2. Ruhnau К J. et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diab. Med. 1999,16:12:1040-43.
3. Reljanovic M., Reichel G.,Rett K. et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year randomized double-blind placebo-controlled trial (ALADIN II) Free Radic. Res.-1999,31:171-9.
4. Pershadsingh H.A. Alpha-lipoic acid: physiologic mechanisms and indications for the treatment of metabolic syndrome. Expert Opin. Investig. Drugs -2007,16 (3), 291 -302.
5. MMWR State-specific prevalence of obesity among adults - United States, 2005, 55:985-8.
6. Kahn B.B., Alquie R.T., Carling D., Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modem understanding of metabolism. Cell Metab. 2005,1:15-25.
7. Long Y.C., Zierath JR. AMP-activated protein kinase signaling in metabolic regulation /Clin. Invest. 2006,116:1776-83.
8. Andersson U., Filipson K., Abbott C.R. et al. AMP-acrivated protein kinase playsa role in the control of food intake/ Biol Chm. 2004,279(13):12005-8.
9. Minokoshi Y., Alquier T., Furukawa N. et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature, 2004,428:569-74.
10. Casanueva F.F. Neuroendocrinology of leptin and ghrelin.//Abstracts of 11th Meeting of the European Neuroendocrine Association. Napoli, 2004, P. 78.
11. Kim M.S., Park J.Y., Namkkong С. etal. Anti-obesity effects of a-lipoic acid mediated byuppression of hypothalamic AMP-acrivated protein kinase. Nat. Med., (2004) 10:727-33.
12. Lee W.J., Koh E.H., Won J.C., Kim M.S., Park J.Y., Lee K.U. Obesity: the role of hypothalamic AMP-activated protein kinase in body weight regulation, bit. J., Biochem. Cell. Biol. 2005,37:2254-9.
13. Song K.H., Youn J.Y., Nam Koong C. et al. Anti-obesity effects of Alpha-Lipoic acid in OLEFT rats. Korean. Diabetes. Assoc. 2002; 26 (6): 464-73.
14. Hansel J.F., Giral P., Nobecourt E. et al. Metabolic syndrome is associate with elevated oxidative stress and dysfunctional dense high - density lipoprotein particles impaired antioxidative activity. J Clin Endocrinology Metab., 2004,89 4963 - 71.
15. Walczak R., Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism // J. Upid. Res. - 2002; 43:177 -86.
16. Linnane A.W., Eastwood H. Cellular redox regulation and prooxidant signaling systems: a new perspective on the free radical theory of aging, Ann. NY Acad. Sci. 2006, 1067:47-55.
17. Willson T.M., Lambert M.H., Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease//Annu. Rev. Biochem. -2001; 70:341-67.
18. Paradise N.F., Pilati C.F., Payne W.R., Finkelstein J.A. Left ventricular function of the isolated, genetically obese rat's heart. Am. J. Physiol. (1985) 248:H438-H444.
19. Chiu H.C., Kovac S.A, Ford D.A. et al. A novel mouse model of lipotoxic cardiomyopathy/Clin. Invest. (2001) 107:813-22.
20. Мехтиев С.Н., Гриневич В.Б., Бращенкова А.В., Кравчук Ю.А. Современные подходы к лечению неалкогольного стеатогепатита. Формирование стандарта терапии. Consilium Medicum 2007,9(9): 79-83.
21. Bilska A, Wlodec L. Lipoic acid - the drug of the future? Pharmacol. Rep. (2005) 57:570-7.
22. Unger R.H.: Lipotoxic diseases. Ann. Rev. Med. (2002) 53:319-336.
23. Mcgavock J.M., Victor R.G., Unger R.H., Szczepaniak LS. Adiposity of the heart, revisited.Ann. Intern. Med. (2006) 144:517-24.
24. Lee Y., Naseem R.H., Duplomb L. et al. Hyperleptinemia prevents lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. Proc. Natl. Acad. Sci. USA (2004) 101:13624-9.
Review
For citations:
, Potential opportunities for treatment of metabolic syndrome withalpha-lipoic acid (Berlithion®300). Obesity and metabolism. 2009;6(3):10-14. (In Russ.) https://doi.org/10.14341/2071-8713-5240
Views:
1067
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
